Clinical Trial

To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the tolerability, pharmacokinetics, and pharmacodynamics of consecutive Multiple treatment for 12 weeks（84 Days） in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis. Participants will receive either IMM-H014 or placebo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-04.
Trial Details
NCT Number NCT07016633
Lead Sponsor Changchun Intellicrown Pharmaceutical Co. LTD
Conditions Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Enrollment 40 participants
Start Date 2025-06-10
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-13